Companies Dominating the NTRK Fusion Gene Positive Advanced Solid Tumor Market
- Zai Lab
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pyramid Biosciences Inc.
- Bayer A.G.
- Merck & Co., Inc.
- Hoffman-La Roche AG
- Pfizer Inc.
- Plexxikon
- OncoDNA
- NeoGenomics Laboratories Inc.
- Cephalon, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of NTRK fusion gene positive advanced solid tumor is assessed at USD 145.16 million.
The NTRK fusion gene positive advanced solid tumor market size was valued at USD 138.94 million in 2024 and is expected to reach USD 282.14 million by 2037, registering around 5.6% CAGR during the forecast period i.e., between 2025-2037. Growing trend for personalized treatment, increased prevalence of solid cancer types, and growing technological advancements in genetic testing will drive the market growth.
North America industry is estimated to hold largest revenue share of 35% by 2037, due to expansion of clinical research and development initiatives in the region.
The major players in the market include Zai Lab, Pyramid Biosciences Inc., Bayer A.G., Merck & Co., Inc., Hoffman-La Roche AG, Pfizer Inc., Plexxikon, OncoDNA, NeoGenomics Laboratories Inc., Cephalon, Inc.
